Murphy, Alexander D, Porter, Catharine ORCID: https://orcid.org/0000-0003-1851-0677, White, Ann, Irving, Alys, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Ray, Ruby, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Mahmood, Reem D., Karanth, Suman, Zhou, Cong, Pugh, Julia, Wheeler, Chelsey, Roberts, Victoria, Arnetoli, Giorgio, Salih, Zena, Hasan, Jurjees, Mitchell, Claire, Morgan, Robert D., Clamp, Andrew R. and Jayson, Gordon C. 2024. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial. International Journal of Gynecological Cancer 34 , pp. 1034-1040. 10.1136/ijgc-2024-005455 |
Jayson, G., Carucci, Margherita, Hurt, Christopher ORCID: https://orcid.org/0000-0003-1206-8355, Zhou, Cong, Monaghan, Phillip, Wych, Julie, Irving, Alys, Narasimham, Monica, Morrison, Hilary, Campbell, Sue, Glasspool, Rosalind, Longo, Mirella ORCID: https://orcid.org/0000-0002-9867-3806, Nelson, Annmarie ORCID: https://orcid.org/0000-0002-6075-8425, Dive, Caroline, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243 and Clamp, Andrew 2021. VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer. Presented at: NCRI Cancer Conference, 2021. |